Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001140361-25-004890
Filing Date
2025-02-14
Accepted
2025-02-14 17:09:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5155
  Complete submission text file 0001140361-25-004890.txt   7124
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Subject) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-58217 | Film No.: 25630757
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 399 PARK AVENUE NEW YORK NY 10022
Business Address 399 PARK AVENUE NEW YORK NY 10022 212-287-6787
Blue Owl Capital Holdings LP (Filed by) CIK: 0001858703 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G